- Home
- TRU vs NTRA Comparison
TRU vs NTRA Comparison
Compare TRU & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRU
- NTRA
- Stock Information
- Founded
- TRU 1968
- NTRA 2003
- Country
- TRU United States
- NTRA United States
- Employees
- TRU N/A
- NTRA N/A
- Industry
- TRU Finance: Consumer Services
- NTRA Medical Specialities
- Sector
- TRU Finance
- NTRA Health Care
- Exchange
- TRU Nasdaq
- NTRA Nasdaq
- Market Cap
- TRU 18.0B
- NTRA 18.4B
- IPO Year
- TRU 2015
- NTRA 2015
- Fundamental
- Price
- TRU $82.94
- NTRA $141.41
- Analyst Decision
- TRU Buy
- NTRA Strong Buy
- Analyst Count
- TRU 12
- NTRA 17
- Target Price
- TRU $116.55
- NTRA $179.00
- AVG Volume (30 Days)
- TRU 2.0M
- NTRA 1.8M
- Earning Date
- TRU 04-24-2025
- NTRA 05-08-2025
- Dividend Yield
- TRU 0.55%
- NTRA N/A
- EPS Growth
- TRU N/A
- NTRA N/A
- EPS
- TRU 1.45
- NTRA N/A
- Revenue
- TRU $4,183,800,000.00
- NTRA $1,696,911,000.00
- Revenue This Year
- TRU $6.15
- NTRA $13.56
- Revenue Next Year
- TRU $10.74
- NTRA $18.11
- P/E Ratio
- TRU $57.35
- NTRA N/A
- Revenue Growth
- TRU 9.20
- NTRA 56.75
- 52 Week Low
- TRU $66.07
- NTRA $83.13
- 52 Week High
- TRU $113.17
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- TRU 40.72
- NTRA 39.10
- Support Level
- TRU $82.77
- NTRA $146.35
- Resistance Level
- TRU $88.81
- NTRA $155.64
- Average True Range (ATR)
- TRU 2.71
- NTRA 6.10
- MACD
- TRU 0.20
- NTRA 0.38
- Stochastic Oscillator
- TRU 35.15
- NTRA 25.42
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries, and about a quarter of its revenue comes from international markets.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.